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Abstract
During follow-up in antimalarial drug trials, treated subjects can be newly infected. PCR correction
is used to distinguish this re-infection from drug failure (recrudescence) and to adjust final drug
efficacy estimates. The epidemiological, biological and technical limitations of PCR correction and
how this may lead to misclassification in drug trial outcomes are underappreciated. This article
considers these limitations and proposes a framework for reporting, interpreting, and improving PCR
correction of antimalarial trials.
Clinical trials of antimalarial drugs: the role of PCR correction
Because of the high prevalence of chloroquine (CQ)- and sulfadoxine-pyrimethamine (SP)-
resistant Plasmodium falciparum infections, artemisinin-containing combination therapies
(ACT) are now being increasingly deployed. However, resistance to artemisinins and ACTs is
emerging in Southeast Asia [1,2]. In order to develop new ACTs, Phase III studies comparing
new regimens with existing regimens are needed. However, particular difficulties arise with
study design and the end points used for these trials (see Box 1) [3-5]. A conventional
‘superiority’ trial design does not apply when the novel regimen of interest is being tested
against an existing regimen of high efficacy, like an ACT; thus non-inferiority trials are more
appropriate. However, non-inferiority trials tend to be large, so the choice of endpoint is critical
(See Box 1). Typically, antimalarial trials use ‘PCR-corrected’ parasitological failure as an
endpoint [5,6], but the estimate of drug efficacy thus obtained is vulnerable to misclassification
errors [4].
How well does ‘PCR correction’ correctly correct? In this paper, we will consider the role of
PCR correction of P. falciparum antimalarial trials in the ACT era, and present its
epidemiological, biological and technical limitations. We will also discuss the consequences
of misclassification by PCR correction and propose a framework for reporting, interpreting,
and improving PCR correction of antimalarial trials.
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Multiplicity of Infection (MOI)
Individuals infected with P. falciparum typically harbour a mixture of genetically distinct
variants (also called genotypes, clones or strains). These variants represent genetically distinct
P. falciparum parasite populations resulting from multiple infected bites or bites from
mosquitoes bearing multiple variants. Using nested PCR amplification with gel electrophoresis
of the polymorphic parasite genes encoding merozoite surface protein 1 (msp-1), merozoite
surface protein 2 (msp-2) and glutamate-rich protein (glurp), the first recognition of the genetic
complexity of falciparum infections was made by Snounou and colleagues in the 1990s [7,8].
Although these have become the standard methods for studying parasite diversity and
multiplicity, other genotyping techniques have also been described [9-15]. These include tri-
nucleotide repeats (microsatellite) genotyping, capillary electrophoresis, Southern blotting,
single-strand conformational polymorphisms (SSCP), PCR-RFLP-SSCP and heteroduplex
tracking assays (HTAs). Each of these methods has advantages and disadvantages, but it is
clear that none of them is capable of detecting all parasite variants within a sample [10]. The
range of MOI has been reported from a single variant to >10 variants in an isolate and can vary
over time in an individual [16-19].
PCR correction – an oxymoron?
Antimalarial efficacy trials assess drug cure rates by following patients after treatment for
sufficient time to ‘capture’ all or most treatment failures [5]. This period of follow-up can range
from 28 days (recommended as a minimum duration by WHO), up to 63 days, depending
primarily on the elimination kinetics of the drug being studied [5,20]. Recurrent parasitemia
observed during this follow-up period is of three broad types: (i) parasites that were present in
the blood before or during treatment;(ii) parasites inoculated prior to initiation of treatment
which emerge from the liver after completion of treatment; (iii) parasites derived from a post-
treatment inoculation. Although it would be useful for an antimalarial treatment to prevent any
type of recurrent infection (a post prophylactic effect) (see Box 1), prevention of recrudescent
infections is generally considered the hallmark of antimalarial efficacy. But how do you
distinguish recrudescence from recent liver emergence in the face of highly complex infections
and frequent reinfections? This is the role of PCR correction (Box 2).
In order to standardize methodology for PCR correction, the WHO convened a meeting of
experts in May 2007 in Amsterdam, The Netherlands, where a number of definitions were
agreed and Guidelines were produced for genotyping to define reinfections and recrudescences
[21] (http://apps.who.int/malaria/docs/drugresistance/MalariaGenotyping.pdf). In theory, the
procedure is straightforward. Comparisons of the pre- and post-treatment msp1, msp2, and
glurp electrophoresis patterns are used to distinguish recrudescences from reinfections (Box
2). However, in practice, the actual implementation of PCR correction is affected by five
potential sources of error: (i) asynchronous sequestration of distinct genotypes, removing them
from the peripheral blood; (ii) lack of sufficient sensitivity of methods to detect minority
variants (<10–20% of the parasite population); (iii) over-amplification of abundant DNA
sequences, particularly with nested PCR, drowning out competing sequences; (iv) direct effects
of antimalarial treatment on the abundance and composition of the within-host parasite
population; and (v) the possibility of re-infection by a new parasite with the same genotype (at
the locus or loci examined) as pre-treatment parasites.
The first three of these sources of error synergise, making it is almost impossible to sample
exhaustively the genotypes present in any P. falciparum infection, particularly when parasite
isolates are typically collected in clinical trials from a single finger-prick blood sample of less
than 100 μl. The major effect of this will be to miss genotypes in the pre-treatment sample and
then incorrectly classify a recurrence as a re-infection when this band appears post-treatment.
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This will lead to an overestimation of ‘new infections’. Although no current method captures
the complete MOI within an individual, heteroduplex tracking assays (HTAs) have been shown
to have sufficient sensitivity to identify minority variants in mixed malaria infections [10,12,
13,22-25]. This technique has been validated and used extensively to study other polyclonal
infections, such as HIV [26-28]. Recently, an evaluation of six recurrent parasitaemias from
trials in Southeast Asia provided the first direct evidence of this type of misclassification. These
samples were classified by conventional genotyping as ‘new infections’. However, using a
HTAs for msp-1 and msp-2, the investigators classified 5 of 6 samples as recrudesences [10].
The shared alleles were confirmed in one patient by cloning and sequencing. These results are
consistent with the clinical history: the patients were either kept in hospital during follow-up
(and thus protected from additional mosquito bites), or they stayed in a region where there is
extremely low transmission and a small chance of re-infection. This type of misclassification
may also explain the results of Mugittu et al. in a trial in Uganda comparing SP to Artesunate-
SP. Using standard genotyping methods, these investigators found a high rate of early ‘new
infections’ (5 of 26 [19.2%] failures at Day 7) [29] despite the fact that the typical pre-patent
period for malaria infections is 6-12 days. The new genotypes, detected at Day 7, could have
derived from unseen minority variants present before treatment.
Minority variant drug-tolerant parasites, which are present (but undetected) before treatment,
can grow up to higher densities after the removal of dominant drug-sensitive genotypes by
drugs. In animal models with mixed wild-type and resistant parasites, the drug-resistant
parasites are competitively released by drug, growing to a higher density than the mixture does
in the absence of drug [30]. There is indirect evidence that this occurs in human malaria
infections [16,31-34]. For example, in six imported falciparum malaria cases in the UK treated
with either atovaquone-proguanil or quinine-SP, recrudescences consisting of drug-resistant
parasites occurred 21 and 42 days after treatment, respectively [35,36]. These infections could
not have been caused by intervening inoculations. In addition, a recent report described the
emergence of drug resistant parasites in pregnant women consistent with competitive release
of drug resistance variants after intermittent preventive therapy [32]. Thus, a ‘new’ variant that
appears after treatment could simply be an unseen minority variant with increased fitness (from
the therapy) that was present before treatment. This is best illustrated by the demonstration that
artemether-lumefantrine ‘selects’ particular pfmdr1 genotypes among ‘new infections’ in in
vivo studies [37,38].
The errors described above lead to overestimation of drug efficacy. The final source of error,
coincidental re-infection by the same genotype present before treatment, can lead to
underestimation of efficacy. The basis for this lies in the fact that, for any given genotype
present in a patient before treatment, there is a finite possibility that a patient might be re-
infected with that genotype after treatment, even if the patient is initially cured. Both
Greenhouse et al. and Kwiek et al. measured the prevalence of individual genotypes among
all patients in clinical trials in Malawi and Uganda, as an estimate of the genotype prevalence
within the communities in which the studies were performed [12,39]. Both studies were
conducted in areas of high transmission and high genetic diversity, and estimated that ~20–
40% of PCR-corrected recrudescences were actually re-infections. This type of error can occur
both in areas with high transmission and in areas of low transmission. In the first case, a high
inoculation rate increases the likelihood of re-infection with the same variant, even if it is
uncommon. In the second case, although MOI will tend to be low, reinfection with a highly
prevalent genotype is likely. In all areas, each subject's home or micro-environment is likely
to contain mosquitoes with the same variants present before he or she was treated.
These opposite sources of error, and a theoretical model to describe their influence, are
illustrated in Figure 1. The question remains: how important is this misclassification? There
is still little direct evidence of the extent of overestimation of efficacy rates. Correctly
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reclassifying the four Cambodian re-infections as recrudescences in Juliano et al. would change
the PCR corrected failure rate for Artesunate–Mefloquine from 18.8% to 21%, similar to the
21.4% unadjusted failure rate [10,40]. In terms of underestimating efficacy rates, correcting
for coincidental reinfection by the same variant present before infection requires more complex
statistical methods [12,41]. Kwiek et al. used a binomial probability algorithm to adjust SP
treatment failures in an IPTp trial. They found an adjusted failure rate of 21.5%, instead of the
unadjusted rate of 24.8%. Thus, either type of misclassification probably only accounts for a
few percentage points of error.
Does a 2–3% error mean anything for the results of a trial? The likely answer is ‘yes’. In the
case of a Phase III non-inferiority trial, where the delta margin (Box 1) might be set at 5%, this
amount of error could significantly impact the interpretation of results. In the case of monitoring
drug efficacy by control programs, as the WHO currently recommends changing first-line
antimalarials if clinical efficacy drops below 90%, errors in this range could have a profound
impact on policy decisions [20]. Furthermore, the relative importance of opposite sources of
error will differ between trial sites as transmission intensity, levels of acquired immunity,
prevalence of parasite resistance, the choice of antimalarial used and the genetic complexity
of the parasite population vary. This jeopardises the validity of multisite comparisons.
Due to these potential sources of error, some investigators have suggested that PCR correction
in clinical trials should be abandoned, especially in areas of high transmission [5,42]. The
primary argument behind this is the belief that re-infections and recrudesences are of equal
importance in these settings. Is the correct identification of recrudescent parasitemia always
important? Yes and no. In a phase III trial, where approval of a drug might depend on small
differences in efficacy, the accurate assessment of re-infections and recrudescences is going
to be important. For national malaria control programs, the situation is more complex. The
presence of any parasitemia after treatment, whatever the cause, will have important public
health impacts and affect the ability for continued transmission. However, ignoring PCR
correction would discriminate against the development of drugs with poor post-prophylactic
effect (Box 1) [5], and certainly have implications for the WHO recommendation that at least
90% efficacy is required to retain a front-line antimalarial drug. For now, however, until more
evidence is produced about the relative importance of re-infection and recrudescences for
malaria control, PCR correction will continue to be used in clinical trials and drug efficacy
monitoring. In the following section, we suggest possible solutions to the problems we have
highlighted.
Potential solutions
Should PCR-correction be abandoned? Will it ever be possible to measure true antimalarial
efficacy? The answer to both questions is a qualified ‘no’. There are five actions that can be
taken to facilitate the appropriate measurement of PCR-dependent clinical endpoints: (i)
educate policy makers about the strengths and limitations of PCR correction; (ii) improve study
design and statistical methods to compensate for misclassification and add credibility intervals;
(iii) develop improved genotyping methods; (iv) develop new efficacy endpoints, such as
parasite clearance times [35], that are not affected by super-infection; and (v) conduct trials in
non-endemic regions or isolate patients to prevent the chance of re-infection.
The results of antimalarial efficacy studies can change treatment policies and impact hundreds
of thousands of people. Currently, policy makers use PCR-corrected data and ignore the raw
data on recurrent infections. Better-informed policy decisions could be made using both
sources of data, and scientific journals, editors and reviewers should insist that, when PCR-
corrected efficacy is estimated, uncorrected estimates of efficacy are always reported with a
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similar emphasis from the trial, and comparisons of corrected rates between different trials are
avoided.
Rather than giving a single ‘PCR-corrected’ cure rate, statistical analyses can be developed to
help minimize these errors. Several investigators have published potential methods for
statistically correcting for the chance of re-infection due to the same variant, but these do not
account for all the types of error described above [12,41]. One possibility would be to develop
tools for investigators capable of providing certainty or credibility intervals for PCR correction.
Along the same lines, Bayesian statistics and uncertainty analyses are employed by forensic
scientists doing paternity tests and DNA matches [43]. In order to do this, ‘priors’ (a set of data
that reflects certain assumptions) would need to be established for different epidemiological
settings. Although these explicit assumptions about the degree of misclassification required by
uncertainty analyses may make some researchers uncomfortable, this approach is preferable
to assuming misclassification is entirely absent.
New genotyping technologies can improve the ability to discriminate variants and measure
minority variants. For example, the use of capillary electrophoresis instead of agarose gels
improves the ability to distinguish variants and identify newly infecting genotypes [44]; HTAs
are also an improvement in that they can distinguish variants based on sequence as well as size
diversity and because they can recognize minority variants [10,12,13]. New methods such as
Massively Parallel Pyrosequencing, which have revolutionized studies on in-host diversity of
HIV and other viruses, can be used in malaria [45]. All of these methods have limitations,
especially in cost. Given the rapid progress being made in studying the genetics of malaria and
in genetic technologies, new field-friendly genotyping methods could be achievable in the near
future. If they are, they will have major public health impact.
Equally important are new approaches to the definition of primary efficacy in terms of parasite
clearance rates, which can be measured either microscopically [46] or by quantitative PCR
[35]. These approaches focus on changes in parasite density on Days 1–3, and, as they only
evaluate parasites present at the time of treatment, have the potential to revolutionise the way
we think about antimalarial drug resistance.
Concluding remarks
Policy makers and developers of new antimalarial compounds should continue to use PCR
correction, as long as its limitations are recognized. We also call for continued development
of improved molecular and statistical methods for the analyses of malaria clinical trial results.
It is our belief that uncorrected failure estimates should always be presented, and comparisons
of PCR-corrected failure estimates between different studies should be strongly discouraged.
Box 1. Clinical Trial Design for Antimalarial Drugs
Superiority Trial
A superiority trial is designed to detect a difference between two treatment regimens. This
approach was previously used to compare new antimalarial treatments against failing drugs
such as CQ and SP. In these trials, competing interventions are evaluated for a significant
difference in efficacy for treatment that must be deemed clinically relevant.
Equivalence Trial
An equivalence trial is designed to confirm the absence of a meaningful difference between
treatments. This approach is less commonly used in Phase III development than non-
inferiority trials.
Non-inferiority Trial
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A non-inferiority trial is designed to show that a new treatment is no less effective than an
existing treatment - it may be more effective or have a similar effect. This trial approach is
particularly useful when comparing two highly efficacious drug regimens, such as
comparing ACT therapies. In this design a ‘delta margin’ (which determines the efficacy
benchmark below which the new drug fails to be ‘non-inferior’), must be set a priori. The
measured efficacy of the comparator drug minus the delta margin must be above the
benchmark for the drug to be considered ‘non-inferior’ [4].
Primary Endpoints
The main result, set a priori in the study protocol, which is measured at the end of a study
to see if a given treatment worked. For antimalarial trials, these could include [3]:
• Chemotherapeutic efficacy- How well does it clear parasitemia?
• Combination chemotherapeutic and post treatment prophylactic- How well does
it cure primary parasitemia and prevent secondary infection?
• Clinical risk reduction - How well does treatment reduce post-treatment incidence
of malaria and its complications?
PCR Correction
The use of genetic fingerprinting to determine whether P. falciparum parasites recurring in
a patient's blood after antimalarial therapy are identical or different than those which
occurred prior to therapy [4]. This is used in malaria drug efficacy trials as they typically
occur in endemic regions where during the follow-up period (usually 28-63 days) patients
are at significant risk of reinfection. Fingerprinting occurs by detection of size differences
of polymorphic antigens by PCR and gel electrophoresis or capillary electrophoresis [21].
If a single parasite variant in the recurrent sample is identical to the pre-treatment sample
at any one of three genetic loci, the recurrent parasitemia is considered to be a recrudescence
(drug failure). If the recurrent parasites differ at all loci from the initial parasitemia, the
recurrent parasitemia is considered a reinfection (not a drug failure).
Box 2. Electrophoretic Patterns and Misclassification of Recurrent
Parasitemiaa
Panels (a) and (b) (of Figure I) represent true recrudescent parasitemias. In Panel (a), all
alleles are shared between pre- and post-treatment samples. In Panel (b), the recurrent
parasitemia shares a single variant with the initial parasitemia. Panel (c) shows a true
reinfection, where no alleles are shared between pre- and post-treatment samples. Panel (d)
shows a false recrudescence. In this case the post-treatment sample technically shares an
allele with the pre-treatment. However, this represents a common variant in the population
causing a reinfection. Panel (e) represents a false reinfection, where a cryptic minority
variant is missed in the initial parasitemia and emerges to a detectable level in the recurrent
parasitemia.
A recrudescence is defined as a parasitaemia occurring subsequent to treatment in which
at least one allele at each locus examined is common to both paired samples (Figure I, Panels
(a) and (b)).
A reinfection is defined as a parasitaemia occurring subsequent to treatment in which all
alleles in the post-treatment sample of a patient are completely different from those in the
admission sample, for one or more loci tested (Figure I, Panel (c)).
aDefinitions from Ref. [21]
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The indeterminate category of previous schemes has been dropped, with the general
principle being that, if a recurrent infection does not differ from the pre-treatment infection
at all alleles of a particular marker, it should be considered a recrudescence.
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Figure 1. Theoretical model for influence of misclassification on PCR correction
Misclassification in antimalarial trials will result in erroneous estimates of the clinical efficacy
of a drug. Underestimation of efficacy occurs due to the re-infection of the patient with a
common shared variant which appears to be a recrudescence. This will shift the efficacy rate
to the left on the model. The inability to detect a minor variant at enrolment that later appears
as a recrudescence leads to overestimation of the efficacy rate. These patients will be considered
re-infections rather than ‘failures’ and the efficacy rate will shift to the right on the model.
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Figure I for Box 2.
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